Biocon Limited, a global innovation-driven biopharmaceutical company, has inaugurated its first U.S. manufacturing facility in Cranbury, New Jersey, through its wholly owned subsidiary, Biocon Generics Inc (BGI). The event was graced by the Honourable Governor of New Jersey, Phil Murphy, along with Biocon Chairperson Kiran Mazumdar-Shaw, senior officials, customers, partners and industry leaders.
The company acquired the Oral Solid Dosage (OSD) facility from Eywa Pharma Inc. in 2023 and has since invested over USD 30 million to transform it into a state-of-the-art manufacturing site with an annual capacity of 2 billion tablets. Several products have already been launched from the facility, with more in the pipeline. This investment strengthens Biocon’s U.S. presence, diversifies its manufacturing base, and enhances supply chain resilience while accelerating its global expansion.
The Cranbury facility is a key milestone in Biocon’s U.S. operations, ensuring faster access to essential therapies, improved supply reliability and closer collaboration with partners and healthcare providers — ultimately benefitting patients across the country.
Kiran Mazumdar-Shaw, Chairperson, Biocon Group, said, “Our first U.S. FDA-approved formulations facility in New Jersey marks an important step in Biocon’s global growth journey. More than a milestone, it reflects our mission to serve patients wherever they are. Governor Phil Murphy’s presence underscores Biocon’s role in driving innovation, creating jobs and strengthening the U.S. healthcare ecosystem. This facility reaffirms our commitment to deeper engagement with healthcare providers, innovators and communities to build a healthier and more equitable future.”
Siddharth Mittal, CEO and Managing Director of Biocon Ltd, added, “We are honoured to have Governor Phil Murphy and our Chairperson join us to celebrate this milestone. This strategic investment brings us closer to patients and partners in this key market. The proximity will enable us to deliver our high-quality, vertically integrated medicines more efficiently, ensuring supply chain resilience and advancing our mission of expanding access to affordable therapies worldwide.”
Governor Murphy said, “We are thrilled that Biocon has chosen New Jersey for its first U.S. manufacturing facility. For years, Biocon has provided high-quality medicines to millions of patients worldwide. This cutting-edge facility marks a significant moment in the company’s global expansion and reinforces New Jersey’s reputation as the medicine chest of the world.”